4 pharmaceutical stocks closed at the limit higher, with some stocks up 167% in the past month

According to data from the Flush Data Center, at the close of trading on November 28, many pharmaceutical stocks rose to the limit, including Tailin Biotechnology, Rongshang Medical, Teyi Pharmaceutical, Fengyuan Pharmaceutical, etc.
, in addition, Yixintang and Kefu Medical rose by more than 7%.

Among them, Tailin Biotech closed at 69.
40 yuan, an increase of 20.
01%, with a turnover of 647 million, a turnover rate of 36.
71%, a price-to-earnings (TTM) of 84.
35, and a total market value of 5.
771 billion
.
The stock has risen by 21.
38%
in the past three days.
Tailin Biotech belongs to the medical device industry, the company's main business is microbial detection and control technology system products, organic analysis instruments and other pharmaceutical equipment research and development, manufacturing and sales
.
The company's main products are microbial detection technology series, isolation technology series, sterilization technology series of various consumables, instruments and equipment
.
On the news, recently, the company said on the interactive platform that Wantai Biotech and its affiliates have purchased the company's microbial detection series, sterilization series and isolation series of products
.
NC membrane, the company has contact with Wantai Biotech and samples, but there is no sales
yet.
Shangrong Medical Shangrong Medical closed at 6.
33 yuan, with a turnover of 335 million, a turnover rate of 8.
71%, and a loss in price-to-earnings (TTM), with a total market value of 5.
347 billion
.
The stock has risen 17.
42%
in the past three days.
It is worth mentioning that the stock has risen 13 times
in the past year.
The company's medical industry, the main business is the production and sales of medical products, medical services, health industry operations, etc
.
The company's main products include medical professional engineering, medical equipment sales and hospital logistics hosting services
.
In addition, the company announced on June 28, 2022 that its medical consumables revenue is mainly operated
by Hefei Pulder Medical Products Co.
, Ltd.
The medical consumables sold by Puls Medical are mainly medical nano-antibacterial and antiviral composite materials, disposable surgical kits, disposable surgical gowns and protective clothing
.
Special Pharmaceutical Special Pharmaceutical closed at 29.
89 yuan, with a turnover of 1.
777 billion, a turnover rate of 38.
95%, a price-to-earnings (TTM) of 55.
79, and a total market value of 6.
796 billion
.
The stock has risen 6.
25%
in the past three days.
It is worth mentioning that since October, the stock price of Teyi Pharmaceutical has continued to rise, during which it has successively harvested the price limit, Choice data shows that from October 10 ~ November 22, the stock price of Teyi Pharmaceutical has risen by 167.
07%.

The unit is a leading stock of traditional Chinese medicine, mainly engaged in the research and development, production and sales
of Chinese proprietary drugs, chemical preparations and chemical raw materials.
The company's main products include cough suppressant tablets, Pudi blue anti-inflammatory tablets, cold spirit granules, compound houttuynia tablets, pharyngitis tablets, blood plug dispersible tablets, ginkgo biloba dispersible tablets, Yixinshu granules, aluminum magnesium carbonate chewable tablets
.
On the news, on November 17, Teyi Pharmaceutical concentrated on disclosing the relevant information of the company's core product cough suppressant tablets, and gave the vision
of "annual sales of 2.
4 billion tablets".
Fengyuan Pharmaceutical Fengyuan Pharmaceutical also closed with a price of 11.
79 yuan, a turnover of 931 million, a turnover rate of 25.
52%, a price-to-earnings (TTM) of 25.
95, and a total market value of 3.
916 billion
.
The stock has risen 1.
09%
in the past three days.
According to the analysis, the reasons for the change in the stock include: the company's main business is the research and development, production and sales of biological drugs, chemical drugs and traditional Chinese medicines; Pharmaceutical distribution and pharmacy retail
.
The company produces ophthalmic drugs; Likang Pharmaceutical, a wholly-owned subsidiary, has been preparing to build a project with an annual output of 30,000 tons of erythritol since 19 years; According to the 2021 annual report, the company's cinidipine tablet products are used for the treatment of hypertension; Anhui Fengyuan Pharmacy Chain Company, a wholly-owned subsidiary, is mainly engaged in the sales of Chinese and Western medicines, medical devices, health foods, etc
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.